CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary Financial performance for FY 2024 (Growth numbers at constant exchange rates) Total Revenue up 21% to $54,073m ...

AstraZeneca PLC beat Q4 and full-year 2024 earnings estimates, with significant revenue and EPS growth, and forecasts further growth in 2025 despite China-related setbacks. The company faces ...

AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. Read why AZN stock is a Buy.

Reports Q4 revenue $14.89B, consensus $13.34B. The company said, “Our company delivered a very strong performance in 2024 with Total ... Read More on AZN: AstraZeneca NewsMORE Related Stocks ...

AstraZeneca PLC (NASDAQ:AZN) is facing ongoing investigations in China regarding suspected unpaid importation taxes, which could result in significant fines. The company experienced a 3% decline in Q4 ...

Reports Q4 revenue $1.99M vs $33.22M last year. “2024 has been an important year for Cellectis (CLLS): we are now developing three programs in ...

Cellectis demonstrated robust performance in Q4 2024, significantly outperforming market expectations. The company’s strategic initiatives, including its partnership with AstraZeneca ...